Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

THE WOODLANDS, Texas, Feb. 21, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2012.

"We continued to make significant progress in the development of our pipeline in 2012, highlighted by positive results from clinical studies of LX4211 in diabetes and telotristat etiprate in carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We are pleased to have commenced the Phase 3 program for telotristat etiprate in carcinoid syndrome, and continue to progress in our preparations for LX4211 Phase 3 initiation. We also look forward to significant proof-of-concept results in irritable bowel syndrome (IBS) with LX1033, ulcerative colitis with telotristat etiprate, and type 1 diabetes with LX4211 in 2013."

Key Developments in 2012

  • LX4211:  Lexicon reported positive results from a 12-week Phase 2b clinical trial of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) in patients with type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy. LX4211 treatment produced substantial, dose-dependent and statistically-significant reductions in hemoglobin A1c (HbA1c), with patients in the high dose (400 mg QD) LX4211 treatment arm having a mean HbA1C reduction from baseline of 0.95 percent (p<0.001). In patients randomized to placebo, HbA1C decreased by 0.09 percent. LX4211 treatment also produced significant reduct
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon To Present At The BIO CEO & Investor Conference
    2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    4. Lexicon to Provide Third Quarter 2012 Financial Results
    5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    9. Lexicon to Provide Second Quarter 2012 Financial Results
    10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... Ill. , Dec. 19, 2014   Hospira, ... leading provider of injectable drugs and infusion technologies, today ... Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, ... presentation is scheduled to begin at 10:30 a.m. Pacific ... available to all interested parties through a live audiocast ...
    (Date:12/19/2014)... -- Monarch America Inc. (OTCQB: CANK) ("Monarch America" or the ... this review of the Company,s recent achievements and strategic ... this past year, we achieved many of our early ... say that Monarch America is in a stronger and ... stated Eric Hagen , CEO of Monarch America ...
    (Date:12/19/2014)... , Dec. 18, 2014 Somewhere between dropping ... health was forgotten. But Audicus , a next-generation ... better this new year. Hearing loss is ... aging population, though it is often unaddressed. Forty-eight million ... has a hearing aid, mainly due to price. Hearing ...
    Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2
    ... 1, 2010 ACCESS PHARMACEUTICALS, ... a biopharmaceutical company leveraging its proprietary drug-delivery ... supportive care and diabetes, announced it has ... recently enacted Patient Protection and Affordable Care Act, cash ...
    ... 2010 The National Quality Forum (NQF) announces ... eight member councils.   NQF is ... the quality of American healthcare by setting national ... consensus standards for measuring and publicly reporting on ...
    Cached Medicine Technology:Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants 2National Quality Forum Members Elect New Council Leaders 2
    (Date:12/20/2014)... Developers of FCPX 3rd ... plugin for Final Cut Pro X entitled TranSlice Volume ... allows users to create hand drawn text animations without ... CEO of Pixel Film Studios. “TranSlice Volume 5 was ... an easy to use interface.” , TranSlice Volume 5 ...
    (Date:12/20/2014)... Twin Cities DI Day is recognized as the premier ... financial professionals come together each year to hear up ... to protect their clients and to be inspired by ... of disability. , On September 23rd, 2014, financial professionals ... The 13th Annual Twin Cities DI Day where they ...
    (Date:12/20/2014)... Today, Balfleet.com, one of the most ... offering 50%-70% off on its Mother of the ... mother of the bride dresses from Balfleet.com feature gorgeous ... accessible and takes pride in providing high quality dresses ... offering great discounts on our mother of the bride ...
    (Date:12/19/2014)... Montrose, Colorado (PRWEB) December 20, 2014 It’s ... many, travel is something that is put to the wayside ... those who still have that travel “itch” and that burning ... Inn Montrose accommodates families on their journey to Telluride with ... trip, get visitors to and from the resort, and ensure ...
    (Date:12/19/2014)... Sub Zero Ice Cream is partnering up ... Sunday the 28th from 2pm-6pm at the Expo Center on ... Sarasota, FL. , Inquiries regarding time slots and signing up, ... the donating process, Sub Zero Ice Cream & Yogurt will ... cream. , About Sub Zero Ice Cream & Yogurt ...
    Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2
    ... Safety and Efficacy Study of Zolpidem Tartrate ... an As-Needed BasisEvaluation of Ondansetron Augmentation in ... May 21 Transcept Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization ...
    ... offers patients better results and quicker recovery as ... currently on the market; Now available in powerful ... Palomar Medical Technologies, Inc. (Nasdaq: PMTI ... systems for cosmetic treatments, announced today the success ...
    ... Inc. (MDLH. PK) ( http://www.mitcanada.ca http://www.mitinvest.ca ), ... the Joint Venture Agreement with its Chinese partners. , ... most recent trip to China having completed the negotiations and ... has also received an initial order of 120 Agro-Jet(R) for ...
    ... Challenging Anatomy Consistent with Superior Results from Randomized ... presented today at EuroPCR from an international, post-approval, ... Everolimus Eluting Coronary Stent System demonstrated low rates ... and major adverse cardiac events (MACE) in a ...
    ... finds many women use spending sprees to boost emotional well-being ... -- When dealing with financial worries, some women may actually ... shows. , The poll of 700 women found that 79 ... themselves an emotional boost. About 40 percent listed "depression" and ...
    ... compared to vaginal birth newborns, researchers say , , THURSDAY, ... elective, repeat cesarean section delivery are nearly twice as ... unit (NICU) than those born vaginally after the mother ... , These c-section babies are also more likely to ...
    Cached Medicine News:Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 2Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 3Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 4Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 2Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 3Health News:New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser 4Health News:MIT is pleased to announce that it has signed the Joint Venture agreement with its Chinese partners and has received an initial order of 120 units for Animal vaccination 2Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 2Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 3Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 4Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 5Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 6Health News:Shop 'Til You Drop: You May Feel Better 2Health News:Risk to Baby Rises With Repeat C-Sections 2Health News:Risk to Baby Rises With Repeat C-Sections 3
    ... path that allows users to take full ... potential to combine two units offers fully ... stimulating coil. The ability to change pulse ... level of each Magstim 200 allows for ...
    ... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
    ... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
    ... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
    Medicine Products: